PE20080334A1 - Sales del acido 6-metoxi-8-[4-(1-(5-fluoro)-quinolin-8-il-piperidin-4-il)-piperazin-1-il]-quinolina clorhidrico - Google Patents

Sales del acido 6-metoxi-8-[4-(1-(5-fluoro)-quinolin-8-il-piperidin-4-il)-piperazin-1-il]-quinolina clorhidrico

Info

Publication number
PE20080334A1
PE20080334A1 PE2007000722A PE2007000722A PE20080334A1 PE 20080334 A1 PE20080334 A1 PE 20080334A1 PE 2007000722 A PE2007000722 A PE 2007000722A PE 2007000722 A PE2007000722 A PE 2007000722A PE 20080334 A1 PE20080334 A1 PE 20080334A1
Authority
PE
Peru
Prior art keywords
quinolin
piperazin
piperidin
fluoro
methoxy
Prior art date
Application number
PE2007000722A
Other languages
English (en)
Inventor
Jean Schmid
James J Bicksler
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20080334A1 publication Critical patent/PE20080334A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA FORMA CRISTALINA DE UNA SAL DEL ACIDO MONOCLORHIDRICO DE 6-METOXI-8-[4-(1-(5-FLUORO)-QUINOLIN-8-IL-PIPERIDIN-4-IL)-PIPERAZIN-1-IL]-QUINOLINA QUE TIENE PARAMETROS DE CELULA UNITARIA a=14,4A; b=7,6A; c=28,8A; Y BETA=107,1. SE REFIERE TAMBIEN A UN PROCESO PARA PREPARAR DICHA FORMA CRISTALINA QUE COMPRENDE PRECIPITAR EN UNA SOLUCION ACUOSA, DE PREFERENCIA AGUA Y ETANOL EN UNA RELACION DE APROXIMADAMENTE 1:1 A 1:10. DICHA FORMA CRISTALINA ES INHIBIDOR DE 5HT1A UTIL EN TRASTORNOS RELACIONADOS CON LA COGNICION (DEMENCIA, PARKINSON, ENFERMEDAD DE HUNTINGTON, ALZHEIMER, ENTRE OTROS) O ANSIEDAD (TRASTORNOS OBSESIVO-COMPULSIVO, TRASTORNO DISFORICO PREMENSTRUAL, ANOREXIA NERVIOSA, ENTRE OTROS)
PE2007000722A 2006-06-09 2007-06-08 Sales del acido 6-metoxi-8-[4-(1-(5-fluoro)-quinolin-8-il-piperidin-4-il)-piperazin-1-il]-quinolina clorhidrico PE20080334A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81216806P 2006-06-09 2006-06-09

Publications (1)

Publication Number Publication Date
PE20080334A1 true PE20080334A1 (es) 2008-05-05

Family

ID=38832402

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000722A PE20080334A1 (es) 2006-06-09 2007-06-08 Sales del acido 6-metoxi-8-[4-(1-(5-fluoro)-quinolin-8-il-piperidin-4-il)-piperazin-1-il]-quinolina clorhidrico

Country Status (12)

Country Link
US (1) US20070299083A1 (es)
EP (1) EP2027111A2 (es)
JP (1) JP2009539854A (es)
CN (1) CN101460484A (es)
AR (1) AR061301A1 (es)
AU (1) AU2007258506A1 (es)
BR (1) BRPI0712483A2 (es)
CA (1) CA2653679A1 (es)
MX (1) MX2008015250A (es)
PE (1) PE20080334A1 (es)
TW (1) TW200808741A (es)
WO (1) WO2007146115A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
TW200811144A (en) * 2006-06-09 2008-03-01 Wyeth Corp Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
AR063984A1 (es) * 2006-11-28 2009-03-04 Wyeth Corp Metabolitos de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina, metodos de preparacion, su uso en la fabricacion de medicamentos para el tratamiento de trastornos relacionados con 5-ht1a, composicion farmaceutica que los comprende, compuestos radioetiquetados derivado
US20080226714A1 (en) * 2007-02-16 2008-09-18 Wyeth Sustained-release tablet formulations of piperazine-piperidine antagonists and agonists of the 5-ht1a receptor having enhanced intestinal dissolution
KR101164515B1 (ko) 2009-11-05 2012-07-11 한국 한의학 연구원 인플루엔자 바이러스 유래 질병의 예방 또는 치료용 조성물
MX2019013198A (es) 2017-06-01 2020-01-20 Eisai R&D Man Co Ltd Composicion farmaceutica que comprende un inhibidor de (s)-7-(2metoxi-3,5-dimetilpiridin-4-il)-1-(tetrahidrofuran-3-il)- 1h-pirazolo[4,3-c]quinolin-4(5h)-ona (pde9).
BG67408B1 (bg) * 2019-04-12 2022-01-17 Софарма Ад Перорален лекарствен състав с растителен алкалоид, за лечение на зависимости

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665183A (en) * 1985-12-20 1987-05-12 American Home Products Corp. Process for preparing 6,7,8,9-tetrahydro-10-methylpyrido[1,2-a]indol-9-amines and derivatives thereof useful for the treatment of cognitive impairments
US4624954A (en) * 1985-12-20 1986-11-25 American Home Products Corporation 6,7,8,9-tetrahydro-10-methylpyrido[1,2-a]indol-9-amines and derivatives thereof, useful for the treatment of cognitive impairments
US5219857A (en) * 1986-10-16 1993-06-15 American Cyanamid Company Method of treating cognitive and related neural behavioral problems
US4904658A (en) * 1988-04-15 1990-02-27 American Cyanamid Company Substituted-6H,8H-pyrimido-[1,2,3-cd]purine-8,10-(9H)-diones and substituted-6H,10H-pyrimido[1,2-cd]purin-10-ones
US5260331A (en) * 1989-01-02 1993-11-09 John Wyeth & Brother Limited Composition for treating depression with (S- or O-heteroaryl)alkyl amines
US5422355A (en) * 1989-06-02 1995-06-06 John Wyeth & Brother, Limited Composition for treating depression with (N-heteroaryl)alkylamines
IL101722A (en) * 1991-05-02 1996-05-14 Wyeth John & Brother Ltd History of piperazine, their preparation and pharmaceutical preparations containing them
GB9125615D0 (en) * 1991-12-02 1992-01-29 Wyeth John & Brother Ltd Amines
GB9514901D0 (en) * 1995-07-20 1995-09-20 American Home Prod Piperazine derivatives
US6329368B1 (en) * 1997-05-09 2001-12-11 The Regents Of The University Of California Endocrine modulation with positive modulators of AMPA type glutamate receptors
US6313126B1 (en) * 1999-01-07 2001-11-06 American Home Products Corp Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
IL145209A0 (en) * 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
US6469007B2 (en) * 2000-11-28 2002-10-22 Wyeth Serotonergic agents
UA73619C2 (en) * 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
EP1341779B1 (en) * 2000-12-13 2006-06-21 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production
UA78999C2 (en) * 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
TW200401641A (en) * 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
ATE370955T1 (de) * 2003-07-31 2007-09-15 Wyeth Corp N-sulfonylheterocyclopyrrolylalkylamin verbindungen als 5-hydroxytryptamin-6 liganden.
WO2005070126A2 (en) * 2004-01-08 2005-08-04 The Regents Of The University Of Colorado Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors
RU2006129647A (ru) * 2004-03-02 2008-04-10 Вайет (Us) Макролиды и способы их получения
CA2556771A1 (en) * 2004-03-02 2005-09-15 Wyeth Non-immunosuppressive immunophilin ligands as neuroprotective and/or neuroregenerative agents
TW200602048A (en) * 2004-06-16 2006-01-16 Wyeth Corp Diphenylimidazopyrimidine and -imidazole amines as inhibitors of β -secretase
DE602005017033D1 (de) * 2004-06-16 2009-11-19 Wyeth Corp Amino-5,5-diphenylimidazolon-derivate zur beta-sekretase-hemmung
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
TW200811144A (en) * 2006-06-09 2008-03-01 Wyeth Corp Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline

Also Published As

Publication number Publication date
WO2007146115A2 (en) 2007-12-21
WO2007146115A3 (en) 2008-04-10
US20070299083A1 (en) 2007-12-27
CA2653679A1 (en) 2007-12-21
BRPI0712483A2 (pt) 2012-08-28
TW200808741A (en) 2008-02-16
CN101460484A (zh) 2009-06-17
MX2008015250A (es) 2008-12-17
AR061301A1 (es) 2008-08-20
EP2027111A2 (en) 2009-02-25
AU2007258506A1 (en) 2007-12-21
JP2009539854A (ja) 2009-11-19

Similar Documents

Publication Publication Date Title
PE20080334A1 (es) Sales del acido 6-metoxi-8-[4-(1-(5-fluoro)-quinolin-8-il-piperidin-4-il)-piperazin-1-il]-quinolina clorhidrico
NO20083197L (no) Substituert cinnolin-derivater som GABAA-reseptor modulatorer og metode for deres syntese
PE20070791A1 (es) Sal de dihidrogeno fosfato del acido 2-(3-{6-[2-(2,4-dicloro-fenil)-etilamino]-2-metoxi-pirimidin-4-il}-fenil)-2-metil-propionico
NO20082481L (no) Nye 2-aminoheterosykluser som er nyttige ved behandling av ABETA-relaterte patologier
CY1118332T1 (el) Μεθοδοι παραγωγης κυκλοαλκυλκαρβοξamιδο-πυριδιno βενζοϊκων οξεων
NO20090166L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
CL2011001992A1 (es) Proceso para producir 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]-piperazina que comprende la etapa de precipitar el solvato isopropanol bromhidrato del compuesto a partir de un solvente con mas de 65% (v/v) de isopropanol; proceso de purificacion; y el intermediario solvato isopropanol bromhidrato del compuesto.
HN2006032171A (es) "sales novedosas de lisina de derivados de acido 4-(fenoxialquil) tio)-fenoxiacetico"
NO20090755L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
MX2009007141A (es) Acidos 1-(3-piridinil)pirazol-4-il-aceticos sustituidos, procedimiento para su preparacion y su utilizacion como agentes herbicidas y reguladores del crecimiento de las plantas.
BRPI0812641A2 (pt) "processo de destilação extrativa (ed) aperfeiçoada para desidratar um material de partida aquoso que contém etanol e água, processo aperfeiçoado para desidratar um material de partida aquoso que contém etanol e água"
CR10784A (es) Nuevos derivados de aminopirimidina como inhibidores de plki
BRPI0410711B8 (pt) ácido 4-(acetilamina)-3-[(4-clorofenil)tio]-2-metil-1h-indol-1-acético
CL2010000284A1 (es) Procedimientos para la preparacion de 4-(2-cianoetenil)-2,6-dimetilanilina a partir de 2,6-dimetil-4-sustituida-anilina. (divisional de solicitud 2003-01598)
BRPI0606594A2 (pt) sal de adição de ácido, método de preparação, solução aquosa, bem como uso do mesmo, processo para preparação de piperidin-4-ilamida do ácido 4-(2,6-dicloro-benzoilamino)-1h-pirazol-3-carboxìlico e uso do mesmo, composição farmacêutica e intermediário quìmico
UY29369A1 (es) Nueva sal de 1-(-3-(3-(4-clorofenil) propoxi(propil) -piperidina
AR072962A1 (es) Derivados de pirimidin-4-ona sustituidos
PE20100261A1 (es) Nuevo procedimiento de sintesis de la agomelatina
MA30576B1 (fr) Formes cristallines de la 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine avec inhibition de la reabsorption de la serotonine et de la norepinephrine en combinaison pour le traitement de la douleur neuropathique
NO20084516L (no) Terfenylderivater for behandling av alzheimers sykdom
BR112022010599A2 (pt) Formas sólidas de ácido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil)-1h-benzo[d]imidazol-6-carboxílico, sal de 1,3-dihidróxi-2-(hidroximetil)propan-2-amina
AR078552A1 (es) Derivados de feniloxadiazol como agentes inhibidores de las pgds
PE20080133A1 (es) 5-amino-6-bromo-n-{[1-(tetrahidro-2h-piran-4-ilmetil)-4-piperidinil]metil}-3,4-dihidro-2h-cromen-8-carboxamida como activador del receptor 5-ht4
AR061299A1 (es) Sales de succionato de 6-metoxi -8- [4- (1-(5- fluor) -quinolin -8-il-piperidin-4-il) -piperazin-1-il] -quinolina y formas cristalinas de las mismas
AR075262A1 (es) Compuestos de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno, proceso para prepararlos, composicion farmaceutica que los comprende, sus usos como medicamentos, o en tratamientos o prevenciones de condiciones asociadas con un funcionamiento alterado de los sistemas regulados por la melatonina, sus usos para

Legal Events

Date Code Title Description
FC Refusal